For Immediate Release

Chicago, IL – September 1, 2009 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bayer AG (BAYRY), Bristol-Myers Squibb (BMY), Johnson and Johnson (JNJ), Sanofi-Aventis (SNY) and Pfizer (PFE).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Monday’s Analyst Blog:

A Step Forward for Bayer

The therapeutic area of Atrial Fibrillation (AF) is buzzing with news. We are pleased with the development made by Bayer Schering Pharma, a division of Bayer AG (BAYRY) in this field. The company completed patient enrollment in the phase III study for Rivaroxaban (Xarelto). The study aims to assess the efficacy and safety of this drug against Bristol-Myers Squibb’s (BMY) warfarin, which is primarily used for the prevention of stroke in AF patients.

The study is expected to include about 14,269 patients spanning over 45 countries with results due by next year. Atrial fibrillation is the most common heart rhythm abnormality in the US. An estimated 3 million people in the US have atrial fibrillation, which affects about one in 10 people aged over 70.

Rivaroxaban, jointly developed with Johnson and Johnson (JNJ) is also being studied for the treatment of venous thromboembolism (VTE) and deep vein thrombosis (DVT) (apart from AF). The drug is approved in the European Union (EU) for the prevention of venous blood clots in adult patients who have undergone elective (planned) hip or knee replacement surgery.

Xarelto was submitted in July 2008 for approval to the US Food and Drug Administration (FDA), and the agency’s advisory committee voted 15-2 recommending its approval in the US in March 2009. A final decision is expected later this year. Xarelto offers multi-billion dollar sales potential. Upon approval, J&J will market the drug in the US while Bayer holds ex-US marketing rights.

In July 2009, the US FDA approved Sanofi-Aventis’ (SNY) Multaq, the first new drug for AF to be approved in a decade. Viewing the high unmet need of the AF market, many companies have pipeline candidates this area. Merck is developing vernakalant intravenous for AF patients, for which it is seeking European Medicines Agency (EMEA) approval.

Moreover, Bristol-Myers and Pfizer (PFE) are co-developing apixaban in addition to Boehringer Ingleheim GmbH’s Pradaxa (dabigatran). Though warfarin is widely used to prevent blood clot, it has certain limitations like careful regulation of blood levels to prevent overdose and reaction with some green vegetables. Any of these drugs on approval has the potential to reach blockbuster status.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Mark Vickery
Web Content Editor



Zacks Investment Research